Neoadjuvant radiotherapy with toripalimab, liposomal irinotecan, and capecitabine for pMMR locally advanced low rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1, single-center trial enrolling adults 18–75 with biopsy-confirmed pMMR locally advanced mid–lower rectal adenocarcinoma and high-risk features. Participants receive neoadjuvant radiotherapy combined with the PD-1 inhibitor toripalimab plus liposomal irinotecan and capecitabine prior to planned surgery. The study focuses on safety, tolerability, and preliminary signs of anti-tumor activity including imaging and pathologic responses. Regular clinical visits, laboratory monitoring, and imaging will be used to follow toxicity and tumor response at the Affiliated Cancer Hospital of Shantou University Medical College.

Why it matters

Who can join: the full rules

Here is the updated format for the \*\*Eligibility Criteria\*\* with bullet points for each item:

Inclusion Criteria:

* Age: 18-75 years, no gender restriction
* ECOG score 0-1
* Biopsy-confirmed pMMR (proficient mismatch repair) localized advanced low rectal adenocarcinoma (tumor's lower edge ≤ 10 cm from the anus)
* Presence of the following high-risk factors: T3N+/T4/N2/EMVI+/MRF+/lateral lymph node metastasis/inability to undergo sphincter-preserving surgery
* Routine chest and abdominal CT scans showing no distant metastasis
* Bone marrow function: Neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet count (PLT) ≥ 100 × 10\^9/L, hemoglobin (Hb) ≥ 70 g/L
* Liver function: ALT, AST ≤ 2.5 × ULN (upper limit of normal); total bilirubin ≤ 1.5 × ULN; serum albumin ≥ 3 g/dL
* Kidney function: Serum creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance ≥ 60 ml/min (calculated using the Cockcroft-Gault formula)
* For females and patients with reproductive potential, a negative pregnancy test must be done within 72 hours before starting the treatment, and the patient must agree to avoid pregnancy during the study treatment and for 6 months after the treatment. For males with reproductive potential partners, the patient must agree to use adequate medically approved contraception during and for 90 days after the final study treatment
* Patients must agree to receive the study's neoadjuvant chemotherapy regimen and sign an informed consent form

Exclusion Criteria:

* Patients with a history of other malignancies within the past 5 years (except for cured and non-recurring cancers such as in situ carcinoma, basal cell carcinoma of the skin, etc.)
* Patients with active, uncontrolled bacterial, viral, or fungal infections requiring systemic treatment, defined by persistent signs/symptoms related to infection, which do not improve despite appropriate antibiotics, antiviral treatments, and/or other therapies
* Patients with uncontrolled systemic diseases, including unstable angina, myocardial infarction, congestive heart failure, severe unstable ventricular arrhythmia, history of severe pericardial disease, or other cardiovascular diseases; uncontrolled hypertension (defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg despite appropriate antihypertensive treatment), or a history of hypertensive crisis, hypertensive encephalopathy; uncontrolled diabetes (fasting blood glucose ≥ 10 mmol/L), etc.
* Patients known to be allergic or intolerant to the treatment drugs or excipients used in this study
* Any clinical indicators showing contraindications to chemotherapy and surgery
* Patients using strong inhibitors or inducers of enzymes such as CYP3A4, CYP2C8, and UGT1A1
* Pregnant or breastfeeding women, and female patients of reproductive potential who refuse to use appropriate contraceptive measures during the study
* Patients who participated in other clinical trials within 4 weeks before enrollment
* Patients whom the investigator deems unsuitable for participation in the study

Where it's running

• Shantou University Medical College Cancer Hospital
  Shantou, Guangdong, China Recruiting
• The First Affiliated Hospital of Shantou University Medical College
  Shantou, Guangdong, China Not yet recruiting

Study contacts

• Study coordinator: Jiarui Lin
• Email: zljr@163.com
• Phone: 86-13794112671

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Total neoadjuvant therapy with concurrent tislelizumab for low rectal cancer

  This trial tests whether adding the immunotherapy drug tislelizumab to total neoadjuvant chemotherapy helps adults with low rectal cancer reach a complete response so some can avoid major surgery.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07561060

• Neoadjuvant chemoradiotherapy with or without tislelizumab for ultra-low rectal cancer – RELIEVE-02

  This study tests whether adding tislelizumab to standard chemoradiotherapy and subsequent chemotherapy improves anus preservation in adults with resectable ultra-low rectal cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07132463

• Effects of Tislelizumab with Chemotherapy in Advanced Rectal Cancer

  This study is testing if adding a new drug called Tislelizumab to chemotherapy can help people with advanced rectal cancer have better outcomes before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Guangxi Medical University · Nanning, Guangxi · NCT06254521

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.